Medtronic plc stock gains as fiscal 2027 guidance raised after strong first quarter

Published on 09/08/2026 at 20:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic plc stock is in focus after a strong start to fiscal 2027, with double-digit organic revenue growth and higher full-year guidance supporting a constructive analyst view.

Reinraumfertigung mit Technikern bei Montage medizintechnischer Präzisionsinstrumente — Medtronic plc (ISIN IE00BTN1Y115) Reinraum-Fertigung zeigt Techniker bei der Montage medizinischer Präzisionsinstrumente sorgfältig, Illustration mit AI erstellt.

Medtronic plc stock (ISIN IE00BTN1Y115) is trading firmly supported after the medical technology group reported double-digit organic revenue growth for the first quarter of fiscal 2027 and raised its full-year guidance, according to recent earnings analysis dated September 8, 2026.The Globe and Mail The stronger outlook and broad-based portfolio performance are shaping investor expectations for the coming quarters.

Fiscal 2027 first quarter beats and guidance raised

According to a detailed breakdown of Medtronic's latest results for the first quarter of fiscal 2027, organic revenue increased 13.7 percent year over year, although an extra selling week contributed about 6.7 percentage points to the reported growth, highlighting that underlying demand remains robust but is partly flattered by calendar effects.The Globe and Mail Cardiovascular revenue rose 18.9 percent organically in the quarter, Medical Surgical gained 10.2 percent, and Neuroscience advanced 9.3 percent, showing that growth is not confined to a single franchise but spread across key segments.The Globe and Mail

The same earnings analysis notes that adjusted operating margin in the first quarter of fiscal 2027 expanded by 10 basis points to 23.7 percent, as Medtronic continued to invest in commercialization, acquisitions and growth platforms while still improving profitability.The Globe and Mail Adjusted first-quarter earnings reached USD 1.45 per share, up 15.1 percent year over year and 4.3 percent above the Zacks Consensus Estimate, underlining that the company exceeded market expectations on the bottom line.The Globe and Mail

Higher full-year outlook and investor-day plans

On the back of the stronger start to fiscal 2027, Medtronic's management has raised its full-year organic revenue growth guidance to a range of 7.25 percent to 7.75 percent, compared with the prior range of 6.75 percent to 7.25 percent, effectively adding 50 basis points at the midpoint, according to the same coverage dated September 8, 2026.The Globe and Mail The company also increased its fiscal 2027 adjusted earnings guidance to USD 5.94 to USD 6.00 per share, while the cited consensus estimate stands at USD 5.96 for the current fiscal year and USD 6.36 for fiscal 2028, supporting expectations of steady earnings growth.The Globe and Mail

At a recent healthcare conference presentation summarized on September 8, 2026, Medtronic emphasized that growth is broadening across its mix of robotics, artificial intelligence, new devices and acquisitions, helping to offset pricing and timing challenges in parts of the market.Investing.com In that presentation, management reiterated that its plan to separate the MiniMed diabetes business remains unchanged and that it expects to complete the separation before the end of fiscal 2027, while noting that slight shifts in timing should have limited impact on earnings per share.Investing.com

Analyst ratings and valuation backdrop

Analyst coverage remains constructive on Medtronic plc stock. A recent note dated September 8, 2026 reports that analyst Travis Steed at Bank of America Securities reaffirmed a Buy rating on Medtronic with a price target of USD 110.00, indicating confidence in medium-term upside potential driven partly by mergers and acquisitions. The same report highlights that in another publication on September 3, 2026, UBS also assigned a Buy rating to the shares with a USD 110.00 price target, suggesting a degree of alignment among major banks on the value case.TipRanks

The investing conference summary further notes that Medtronic trades at a price-to-earnings ratio of 22.8 while generating strong cash flows, a valuation that reflects both its improved growth profile and ongoing investment needs.Investing.com Consensus price targets are described as implying roughly 13 percent upside from current levels, which, when contrasted with the raised guidance for fiscal 2027, forms a key part of the risk-reward discussion for investors considering the stock.Investing.com

Risks and opportunities around growth platforms

While growth has accelerated, the same sources caution that some Medtronic businesses still face pricing and timing challenges, particularly in markets where competitive pressure is strong or reimbursement dynamics are evolving.Investing.com Adjusted margin expansion of 10 basis points in the first quarter of fiscal 2027 to 23.7 percent shows that profitability improvement is modest compared with the 13.7 percent organic revenue increase, underlining that higher growth currently comes with continued spending on commercialization and acquisitions.The Globe and Mail

Management has outlined long-term growth ambitions at the Wells Fargo healthcare conference, including expectations for mid-single-digit revenue growth at around 6 percent at the midpoint and high-single-digit earnings per share growth over time, supported by platforms such as cardiac ablation and surgical robotics.Investing.com Brazil In cardiac ablation, the company sees a market that is expected to reach around USD 100 billion annually by the end of fiscal 2026, with its own business aiming to grow more than 2.5 times the market rate in fiscal 2027, where the market itself is projected to expand in the mid-teens around 15 percent.Investing.com Brazil

Representative product: MiniMed diabetes technologies

One of Medtronic's most prominent product lines is its MiniMed portfolio of insulin pumps and diabetes management technologies, which the company intends to separate into its own entity before the end of fiscal 2027, according to the conference remarks dated September 8, 2026.Investing.com The planned separation is part of a broader strategy to sharpen focus and unlock value in growth platforms, while giving the diabetes unit more autonomy to invest in automated insulin delivery, continuous glucose monitoring and digital decision-support tools tailored for people living with diabetes.

Stock price and market context

Recent technical analysis of Medtronic plc stock identifies a current price point of USD 93.04 on the New York Stock Exchange as of a signal overview dated September 8, 2026, with no clear resistance levels remaining above that price in the near term, indicating potential upside if momentum persists.Stock Traders Daily In the same analysis, near-term signals highlight support around USD 93.43 and resistance around USD 95.13 over a one-to-five-day horizon, while longer-term signals place weaker support near USD 82.52 and resistance around USD 90.88, giving investors concrete levels to watch in the coming sessions.Stock Traders Daily

For investors, the combination of a first-quarter fiscal 2027 earnings beat, organic revenue growth of 13.7 percent compared with the prior year and raised full-year guidance to 7.25 percent to 7.75 percent organic growth, together with Buy ratings and USD 110.00 price targets from major banks, sets a constructive backdrop for Medtronic plc stock.The Globe and MailTipRanks Against that, modest margin expansion and ongoing pricing pressure in some businesses are important risk factors to monitor, particularly if the strong start to fiscal 2027 were to moderate in subsequent quarters.